Harnessing pyroptosis to restrain melanoma through aripiprazole

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Melanoma is resistant to apoptosis-based therapies, necessitating novel cell death strategies.
• Pyroptosis is a pro-inflammatory programmed cell death pathway involving caspase-1, gasdermin D, and IL-1β.
• Aripiprazole is an antipsychotic drug with potential anti-cancer applications.

Purpose of the Study:

• To investigate the mechanism by which aripiprazole induces cell death in melanoma.
• To explore the role of pyroptosis and inflammatory signaling in aripiprazole's anti-melanoma effects.
• To identify key molecular targets mediating aripiprazole's anti-cancer activity.

Main Methods:

• Transcriptomic analysis of melanoma cells treated with aripiprazole.
• Assays to detect caspase-1 activation, gasdermin D cleavage, and cytokine release.
• Investigation of the MAPK signaling pathway and cell-cycle progression.
• Genetic and pharmacological manipulation of NOD2 expression and activity.

Main Results:

• Aripiprazole induced pyroptosis in BRAF-mutant melanoma cells, characterized by caspase-1 activation and IL-1β release.
• Aripiprazole activated the MAPK signaling cascade and caused G1 cell-cycle arrest.
• Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) was upregulated by aripiprazole and found to be essential for pyroptosis induction.
• NOD2 mediated both inflammasome activation and downstream signaling pathways (MAPK, NF-κB).

Conclusions:

• Aripiprazole effectively induces pyroptosis in melanoma cells via NOD2-dependent inflammatory signaling.
• Aripiprazole's anti-cancer effects involve pyroptosis, MAPK activation, and cell-cycle arrest.
• Serotonergic drugs like aripiprazole show promise as immunomodulatory agents for cancer therapy.